New Hope Clinical Research, an independent clinical research site, today announced that the U. S. Food and Drug Administration (FDA) concluded its Routine inspection of the New Hope Clinical Trials facility. The inspection took place August 18-26 and reported that New Hope is in full compliance with regulations. The FDA found No observations at the conclusion of the inspection.
“We are very proud of the positive results of the FDA inspection process. These results directly correlate to the high quality of our data, our staff, and our expert investigators. New Hope Clinical Research is focused on finding solutions in collaboration with the Pharmaceutical industry to a wide array of psychiatric diseases from Alzheimer’s to Schizophrenia.
“New Hope Clinical Research is pleased that these outstanding results will further motivate us to provide good Quality Clinical data through every Phase of clinical research,” said Tammy Rader, CEO of New Hope Clinical Research.